Sector Gamma As
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 9, 2024), Sector Gamma As reported 28 stock positions worth $267.7 million. Its top holding was Gilead Sciences (GILD) at 10.8% of the portfolio, followed by Pfizer (PFE, 9.4%) and Bristol-Myers Squibb (BMY, 8.3%). Compared with Q1 2024, it opened 2 new positions, sold out of 2, added to 4 and reduced 22. The biggest buy was Gilead Sciences (GILD, shares +58%) and the biggest sale Medtronic (MDT, shares −36%).
- Most Recent 13F
- Q2 2026
- Location
- OSLO, Q8
- CIK
- 0001475373
- Portfolio Value
- $267.7M (Q2 2024)
- SEC Filing
- 0000945621-24-000640 ↗ filed Aug 9, 2024
Holdings Value
Holdings 28 stocks · $267.7M
| GILD Gilead Sciences Inc. | 10.77% | 420,163 | $28.8M | Add +58.2% |
| PFE Pfizer Inc. | 9.36% | 895,000 | $25.0M | Reduce -27.8% |
| BMY Bristol-Myers Squibb Co. | 8.30% | 535,000 | $22.2M | Add +7.3% |
| MDT Medtronic PLC | 7.79% | 264,890 | $20.8M | Reduce -35.7% |
| ELV Elevance Health Inc. | 4.91% | 24,279 | $13.2M | Reduce -29.2% |
| CVS CVS Health Corp. | 4.85% | 220,000 | $13.0M | Reduce -28.6% |
| INCY Incyte Corp. | 4.61% | 203,376 | $12.3M | Reduce -23.2% |
| CAH Cardinal Health Inc. | 3.93% | 107,098 | $10.5M | Reduce -41.3% |
| BIIB Biogen Inc. | 3.81% | 43,985 | $10.2M | Reduce -26.3% |
| AMGN Amgen Inc. | 3.50% | 30,000 | $9.4M | New |
| ZBH Zimmer Biomet Holdings Inc. | 3.45% | 85,000 | $9.2M | Reduce -29.8% |
| BAX Baxter International Inc. | 3.25% | 260,000 | $8.7M | Reduce -19.5% |
| GEHC GE Healthcare Technology | 3.03% | 104,000 | $8.1M | Reduce -15.5% |
| IONS Ionis Pharmaceuticals Inc. | 3.03% | 170,000 | $8.1M | Reduce -3.1% |
| BRKR Bruker Corp. | 2.75% | 115,472 | $7.4M | Add +2.4% |
| ABT Abbott Laboratories | 2.72% | 70,000 | $7.3M | New |
| THC Tenet Healthcare Corp. | 2.63% | 52,861 | $7.0M | Reduce -31.8% |
| UHS Universal Health Services-B | 2.42% | 35,000 | $6.5M | Reduce -49.9% |
| EW Edwards Lifesciences Corp. | 2.39% | 69,153 | $6.4M | Reduce -35.3% |
| AGIO Agios Pharmaceuticals Inc. | 1.96% | 121,844 | $5.3M | Reduce -25.9% |
| BMRN Biomarin Pharmaceutical Inc. | 1.95% | 63,348 | $5.2M | Reduce -22.2% |
| ALKS Alkermes PLC | 1.75% | 194,000 | $4.7M | Reduce -23.1% |
| BIO Bio-Rad Laboratories-A | 1.72% | 16,829 | $4.6M | Reduce -50.0% |
| ALNY Alnylam Pharmaceuticals Inc. | 1.38% | 15,240 | $3.7M | Reduce -44.8% |
| QGEN Qiagen NV | 1.28% | 83,484 | $3.4M | Reduce -19.2% |
| CNC Centene Corp. | 1.11% | 45,000 | $3.0M | Add +102.6% |
| LNTH Lantheus Holdings Inc. | 0.95% | 31,712 | $2.5M | Reduce -40.2% |
| VTRS Viatris Inc. | 0.41% | 103,106 | $1.1M | Reduce -75.3% |
Portfolio Sells Q1 2024 → Q2 2024
| MDT Medtronic PLC | Reduce -35.7% | 7.79% | −2.33 |
| CVS CVS Health Corp. | Reduce -28.6% | 4.85% | −2.07 |
| CAH Cardinal Health Inc. | Reduce -41.3% | 3.93% | −1.82 |
| GMED Globus Medical Inc. Class A | Sold out | 0.00% | −1.59 |
| BIO Bio-Rad Laboratories-A | Reduce -50.0% | 1.72% | −1.56 |
| UHS Universal Health Services-B | Reduce -49.9% | 2.42% | −1.18 |
| ZBH Zimmer Biomet Holdings Inc. | Reduce -29.8% | 3.45% | −1.06 |
| VTRS Viatris Inc. | Reduce -75.3% | 0.41% | −1.00 |
| ILMN Illumina Inc. | Sold out | 0.00% | −0.66 |
| BAX Baxter International Inc. | Reduce -19.5% | 3.25% | −0.64 |
| EW Edwards Lifesciences Corp. | Reduce -35.3% | 2.39% | −0.49 |
| PFE Pfizer Inc. | Reduce -27.8% | 9.36% | −0.34 |
| ALKS Alkermes PLC | Reduce -23.1% | 1.75% | −0.18 |
| GEHC GE Healthcare Technology | Reduce -15.5% | 3.03% | −0.13 |
| ELV Elevance Health Inc. | Reduce -29.2% | 4.91% | −0.10 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -22.2% | 1.95% | −0.06 |
| LNTH Lantheus Holdings Inc. | Reduce -40.2% | 0.95% | +0.02 |
| QGEN Qiagen NV | Reduce -19.2% | 1.28% | +0.03 |
| BIIB Biogen Inc. | Reduce -26.3% | 3.81% | +0.18 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -44.8% | 1.38% | +0.22 |
| THC Tenet Healthcare Corp. | Reduce -31.8% | 2.63% | +0.33 |
| INCY Incyte Corp. | Reduce -23.2% | 4.61% | +0.35 |
| AGIO Agios Pharmaceuticals Inc. | Reduce -25.9% | 1.96% | +0.61 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -3.1% | 3.03% | +0.88 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $461.0M | BMY, MRK, MDT, PFE, INCY |
| Q1 2026 | 42 | $423.5M | BMY, MRK, PFE, MDT, INCY |
| Q4 2025 | 36 | $438.7M | BMY, MRK, MDT, BDX, GILD |
| Q3 2025 | 41 | $403.3M | PFE, MDT, MRK, BMY, BDX |
| Q2 2025 | 38 | $305.9M | PFE, MDT, BMY, BDX, MRK |
| Q1 2025 | 33 | $312.2M | BMY, PFE, BDX, MDT, AMGN |
| Q4 2024 | 30 | $290.9M | PFE, MDT, BMY, GILD, BDX |
| Q3 2024 | 29 | $329.6M | BMY, MDT, GILD, PFE, CVS |
| Q2 2024 | 28 | $267.7M | GILD, PFE, BMY, MDT, ELV |
| Q1 2024 | 28 | $354.8M | MDT, PFE, BMY, CVS, CAH |